93.99 USD
-2.35 (-2.44%)
93.99 USD
0 (0%)
Taking everything into account, AZN scores 6 out of 10 in our fundamental rating. AZN was compared to 190 industry peers in the Pharmaceuticals industry. While AZN belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. AZN has a correct valuation and a medium growth rate. AZN also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
- AZN had positive earnings in the past year.
- In the past year AZN had a positive cash flow from operations.
- Each year in the past 5 years AZN has been profitable.
- In the past 5 years AZN always reported a positive cash flow from operatings.
1.2 Ratios
- AZN has a better Return On Assets (8.21%) than 89.47% of its industry peers.
- Looking at the Return On Equity, with a value of 20.48%, AZN belongs to the top of the industry, outperforming 90.53% of the companies in the same industry.
- AZN has a Return On Invested Capital of 14.42%. This is amongst the best in the industry. AZN outperforms 93.68% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for AZN is in line with the industry average of 12.84%.
- The last Return On Invested Capital (14.42%) for AZN is above the 3 year average (11.62%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.21% | ||
| ROE | 20.48% | ||
| ROIC | 14.42% |
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.52%
1.3 Margins
- Looking at the Profit Margin, with a value of 16.17%, AZN belongs to the top of the industry, outperforming 88.42% of the companies in the same industry.
- AZN's Profit Margin has improved in the last couple of years.
- AZN's Operating Margin of 24.34% is amongst the best of the industry. AZN outperforms 91.05% of its industry peers.
- AZN's Operating Margin has improved in the last couple of years.
- Looking at the Gross Margin, with a value of 81.90%, AZN belongs to the top of the industry, outperforming 85.26% of the companies in the same industry.
- In the last couple of years the Gross Margin of AZN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 24.34% | ||
| PM (TTM) | 16.17% | ||
| GM | 81.9% |
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), AZN is creating some value.
- The number of shares outstanding for AZN remains at a similar level compared to 1 year ago.
- Compared to 5 years ago, AZN has more shares outstanding
- The debt/assets ratio for AZN is higher compared to a year ago.
2.2 Solvency
- An Altman-Z score of 3.61 indicates that AZN is not in any danger for bankruptcy at the moment.
- AZN has a better Altman-Z score (3.61) than 66.84% of its industry peers.
- AZN has a debt to FCF ratio of 3.41. This is a good value and a sign of high solvency as AZN would need 3.41 years to pay back of all of its debts.
- AZN has a Debt to FCF ratio of 3.41. This is amongst the best in the industry. AZN outperforms 87.37% of its industry peers.
- AZN has a Debt/Equity ratio of 0.61. This is a neutral value indicating AZN is somewhat dependend on debt financing.
- The Debt to Equity ratio of AZN (0.61) is worse than 68.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 3.41 | ||
| Altman-Z | 3.61 |
ROIC/WACC1.63
WACC8.84%
2.3 Liquidity
- AZN has a Current Ratio of 0.88. This is a bad value and indicates that AZN is not financially healthy enough and could expect problems in meeting its short term obligations.
- AZN's Current ratio of 0.88 is on the low side compared to the rest of the industry. AZN is outperformed by 87.89% of its industry peers.
- A Quick Ratio of 0.69 indicates that AZN may have some problems paying its short term obligations.
- Looking at the Quick ratio, with a value of 0.69, AZN is doing worse than 86.32% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.88 | ||
| Quick Ratio | 0.69 |
3. Growth
3.1 Past
- AZN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.61%, which is quite impressive.
- The Earnings Per Share has been growing by 18.59% on average over the past years. This is quite good.
- AZN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 13.52%.
- AZN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.27% yearly.
EPS 1Y (TTM)20.61%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%14.42%
Revenue 1Y (TTM)13.52%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%11.99%
3.2 Future
- The Earnings Per Share is expected to grow by 12.37% on average over the next years. This is quite good.
- AZN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.20% yearly.
EPS Next Y11.95%
EPS Next 2Y12.55%
EPS Next 3Y12.2%
EPS Next 5Y12.37%
Revenue Next Year10.2%
Revenue Next 2Y8.11%
Revenue Next 3Y7.34%
Revenue Next 5Y7.2%
3.3 Evolution
- Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 20.43 indicates a rather expensive valuation of AZN.
- 80.53% of the companies in the same industry are more expensive than AZN, based on the Price/Earnings ratio.
- AZN is valuated rather cheaply when we compare the Price/Earnings ratio to 27.54, which is the current average of the S&P500 Index.
- Based on the Price/Forward Earnings ratio of 17.95, the valuation of AZN can be described as rather expensive.
- Based on the Price/Forward Earnings ratio, AZN is valued a bit cheaper than 78.95% of the companies in the same industry.
- Compared to an average S&P500 Price/Forward Earnings ratio of 24.31, AZN is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.43 | ||
| Fwd PE | 17.95 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, AZN is valued cheaper than 81.58% of the companies in the same industry.
- 81.05% of the companies in the same industry are more expensive than AZN, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 30.46 | ||
| EV/EBITDA | 15.52 |
4.3 Compensation for Growth
- The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
- AZN has an outstanding profitability rating, which may justify a higher PE ratio.
- AZN's earnings are expected to grow with 12.20% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.71
PEG (5Y)1.1
EPS Next 2Y12.55%
EPS Next 3Y12.2%
5. Dividend
5.1 Amount
- AZN has a Yearly Dividend Yield of 1.73%. Purely for dividend investing, there may be better candidates out there.
- AZN's Dividend Yield is rather good when compared to the industry average which is at 0.35. AZN pays more dividend than 92.63% of the companies in the same industry.
- AZN's Dividend Yield is comparable with the S&P500 average which is at 1.92.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.73% |
5.2 History
- The dividend of AZN has a limited annual growth rate of 1.40%.
- AZN has been paying a dividend for at least 10 years, so it has a reliable track record.
- AZN has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)1.4%
Div Incr Years1
Div Non Decr Years11
5.3 Sustainability
- AZN pays out 52.89% of its income as dividend. This is a bit on the high side, but may be sustainable.
- The dividend of AZN is growing, but earnings are growing more, so the dividend growth is sustainable.
DP52.89%
EPS Next 2Y12.55%
EPS Next 3Y12.2%
93.99
-2.35 (-2.44%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)02-10 2026-02-10/amc
Inst Owners49.17%
Inst Owner Change0.13%
Ins Owners0.02%
Ins Owner ChangeN/A
Market Cap291.42B
Revenue(TTM)58.13B
Net Income(TTM)9.40B
Analysts82.42
Price Target97.35 (3.57%)
Short Float %0.28%
Short Ratio1.67
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.73% |
Yearly Dividend2.99
Dividend Growth(5Y)1.4%
DP52.89%
Div Incr Years1
Div Non Decr Years11
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.14%
Min EPS beat(2)-1.74%
Max EPS beat(2)1.47%
EPS beat(4)2
Avg EPS beat(4)2.1%
Min EPS beat(4)-1.74%
Max EPS beat(4)9.32%
EPS beat(8)4
Avg EPS beat(8)0.88%
EPS beat(12)8
Avg EPS beat(12)2.53%
EPS beat(16)12
Avg EPS beat(16)3.75%
Revenue beat(2)0
Avg Revenue beat(2)-0.25%
Min Revenue beat(2)-0.26%
Max Revenue beat(2)-0.24%
Revenue beat(4)1
Avg Revenue beat(4)-0.45%
Min Revenue beat(4)-3.99%
Max Revenue beat(4)2.7%
Revenue beat(8)3
Avg Revenue beat(8)0.07%
Revenue beat(12)4
Avg Revenue beat(12)-0.52%
Revenue beat(16)6
Avg Revenue beat(16)0.18%
PT rev (1m)1.36%
PT rev (3m)7.67%
EPS NQ rev (1m)1.34%
EPS NQ rev (3m)-0.6%
EPS NY rev (1m)-1.9%
EPS NY rev (3m)-1.45%
Revenue NQ rev (1m)0.01%
Revenue NQ rev (3m)0.23%
Revenue NY rev (1m)0.07%
Revenue NY rev (3m)0.52%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.43 | ||
| Fwd PE | 17.95 | ||
| P/S | 5.01 | ||
| P/FCF | 30.46 | ||
| P/OCF | 19.25 | ||
| P/B | 6.35 | ||
| P/tB | N/A | ||
| EV/EBITDA | 15.52 |
EPS(TTM)4.6
EY4.89%
EPS(NY)5.24
Fwd EY5.57%
FCF(TTM)3.09
FCFY3.28%
OCF(TTM)4.88
OCFY5.2%
SpS18.75
BVpS14.8
TBVpS-4.36
PEG (NY)1.71
PEG (5Y)1.1
Graham Number39.14
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.21% | ||
| ROE | 20.48% | ||
| ROCE | 17.6% | ||
| ROIC | 14.42% | ||
| ROICexc | 16.02% | ||
| ROICexgc | 81.56% | ||
| OM | 24.34% | ||
| PM (TTM) | 16.17% | ||
| GM | 81.9% | ||
| FCFM | 16.46% |
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.52%
ROICexc(3y)12.66%
ROICexc(5y)10.55%
ROICexgc(3y)112.76%
ROICexgc(5y)85.06%
ROCE(3y)13.95%
ROCE(5y)11.45%
ROICexgc growth 3Y43.28%
ROICexgc growth 5Y4.77%
ROICexc growth 3Y41%
ROICexc growth 5Y11.99%
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
F-Score7
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 3.41 | ||
| Debt/EBITDA | 1.34 | ||
| Cap/Depr | 84.97% | ||
| Cap/Sales | 9.59% | ||
| Interest Coverage | 10.83 | ||
| Cash Conversion | 73.11% | ||
| Profit Quality | 101.79% | ||
| Current Ratio | 0.88 | ||
| Quick Ratio | 0.69 | ||
| Altman-Z | 3.61 |
F-Score7
WACC8.84%
ROIC/WACC1.63
Cap/Depr(3y)61.87%
Cap/Depr(5y)60.41%
Cap/Sales(3y)7.51%
Cap/Sales(5y)7.64%
Profit Quality(3y)144.6%
Profit Quality(5y)772.45%
High Growth Momentum
Growth
EPS 1Y (TTM)20.61%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%14.42%
EPS Next Y11.95%
EPS Next 2Y12.55%
EPS Next 3Y12.2%
EPS Next 5Y12.37%
Revenue 1Y (TTM)13.52%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%11.99%
Revenue Next Year10.2%
Revenue Next 2Y8.11%
Revenue Next 3Y7.34%
Revenue Next 5Y7.2%
EBIT growth 1Y26.07%
EBIT growth 3Y37.28%
EBIT growth 5Y27.35%
EBIT Next Year32.31%
EBIT Next 3Y16.96%
EBIT Next 5Y13.82%
FCF growth 1Y37.12%
FCF growth 3Y24.58%
FCF growth 5Y70.22%
OCF growth 1Y46.1%
OCF growth 3Y25.76%
OCF growth 5Y31.92%
ASTRAZENECA PLC-SPONS ADR / AZN FAQ
Can you provide the ChartMill fundamental rating for ASTRAZENECA PLC-SPONS ADR?
ChartMill assigns a fundamental rating of 6 / 10 to AZN.
What is the valuation status for AZN stock?
ChartMill assigns a valuation rating of 6 / 10 to ASTRAZENECA PLC-SPONS ADR (AZN). This can be considered as Fairly Valued.
How profitable is ASTRAZENECA PLC-SPONS ADR (AZN) stock?
ASTRAZENECA PLC-SPONS ADR (AZN) has a profitability rating of 9 / 10.
Can you provide the PE and PB ratios for AZN stock?
The Price/Earnings (PE) ratio for ASTRAZENECA PLC-SPONS ADR (AZN) is 20.43 and the Price/Book (PB) ratio is 6.35.
What is the expected EPS growth for ASTRAZENECA PLC-SPONS ADR (AZN) stock?
The Earnings per Share (EPS) of ASTRAZENECA PLC-SPONS ADR (AZN) is expected to grow by 11.95% in the next year.